Innovation Pharmaceuticals announced that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90% and that the Company anticipates full enrollment to be completed in approximately two weeks. Innovation Pharma is developing Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients under U.S. FDA Fast Track designation (see NCT04784897). The Phase 2 study is a randomized, double-blind, placebo-controlled clinical trial evaluating Brilacidin, a synthetic, non-peptidic small molecule drug candidate in anew class of compounds called defensin-mimetics, at domestic and international sites. The Company intends to provide an update to shareholders upon the final patients entering the trial.